Lazar David E. 的 Form 4/A 修正申報
修正Titan Pharmaceuticals Inc（TTNP），2023/6/28 申報
- 申報編號
- 0000921895-23-001593
- 申報時間
- 2023/6/28 16:14 ET
- 交易日
- 2023/6/21
- 申報延遲
- 7 天
- 10b5-1 計畫
- 沒有勾選
- 原始申報日
- 2023/6/23
這份申報列了 2 筆非衍生性交易。公開市場賣出合計 $461.0 萬。交易後 7 天申報。
這份修正申報取代了 0000921895-23-001569（2023/6/23 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Lazar David E.CIK 0001932843 | 董事、高階主管（執行長）、持股 10% 以上大股東 |
| Activist Investing LLCCIK 0001817604 | 其他：Member of 10% owner group |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
These Shares were sold pursuant to a Share Transfer Agreement dated June 21, 2023. As consideration for the transfer, Mr. Lazar received $4,600,000.
表 I 有 2 筆交易的價格引用這則附註。
- F2
Prior to the filing of the Reporting Persons's Form 4 on June 23, 2023, the Reporting Person contacted the Issuer and advised the Issuer of his obligation to disgorge the "short-swing profit" realized by the Reporting Person, and that he was making preparation for payment of such disgorgement. Due to a ministerial error, such informaton was inadvertently excluded from the Form 4 filed by the Reporting Person on June 23, 2023.
表 I 有 2 筆交易的價格引用這則附註。
- F3
This Form 4 is filed jointly by Activist Investing LLC ("Activist Investing") and David E. Lazar (collectively, the "Reporting Persons").
- F4
Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or any other purpose.
- F5
Securities of the Issuer beneficially owned directly by Activist Investing. Mr. Lazar, as the sole member and Chief Executive Officer of Activist Investing, may be deemed the beneficial owner of the securities of the Issuer beneficially owned by Activist Investing.